Get started
Author

Leo V. Lacerna

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer
2006 · Adam Brufsky, W. Graydon Harker, et al. · Journal of Clinical Oncology · 322
PDF
Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006
2007 · Richard Weitzman, Nicholas Sauter, et al. · Critical Reviews in Oncology/Hematology · 185
Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer
2006 · Christopher W. Ryan, Dezheng Huo, et al. · The Journal of Urology · 126
The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy
2007 · Ron S. Israeli, Steven J. Rosenberg, et al. · Clinical Genitourinary Cancer · 108
Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy
2004 · Charles L. Vogel, Ronald H. Yanagihara, et al. · The Oncologist · 77
PDF
Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial
2005 · A. Brufsky, W. G. Harker, et al. · Journal of Clinical Oncology · 54
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors
2003 · L LACERNA · Seminars in Oncology · 43
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases
2005 · Thomas J. Polascik, Robert W. Given, et al. · Urology · 41
P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
2007 · A. Brufsky, K. Lund, et al. · The Breast · 21
P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
2007 · A. Brufsky, N. Bundred, et al. · The Breast · 15
Renal function among cancer patients with bone metastases treated with zoledronic acid in a real world setting
2007 · B. L. Nordstrom, C. Langer, et al. · Journal of Clinical Oncology · 2
Safety of zoledronic acid in patients who have previously received bisphosphonate therapy
2004 · R. Yanagihara, C. L. Vogel, et al. · Journal of Clinical Oncology · 1
410: Bone Mineral Density in Prostate Cancer Patients Undergoing Initial Androgen Deprivation Therapy: Zoledronic Acid VS. Placebo
2006 · Ron S. Israeli, Steven Rosenberg, et al. · The Journal of Urology
Stem Cell Factor
2000 · Leo Lacerna, William Sheridan, et al. · Informa Healthcare eBooks
Works count: 15
Citation count: 995
H-index: 10
I10-index: 10
Year
Topic
Type